Annals of Surgical Oncology

, Volume 14, Issue 10, pp 2854–2860

Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients

  • Martin D. McCarter
  • Joel Baumgartner
  • Guillermo A. Escobar
  • Donald Richter
  • Karl Lewis
  • William Robinson
  • Cara Wilson
  • Brent E. Palmer
  • Rene Gonzalez
Melanomas

Abstract

Background

Immunologic therapies for melanoma rarely succeed, suggesting a persistent counter-regulatory immune modulation. Regulatory T cells (Tregs) and plasmacytoid subpopulations of dendritic cells (pDCs) inhibit the immune response. We hypothesize that melanoma upregulates Tregs and subpopulations of immunosuppressive dendritic cells (DCs).

Methods

Peripheral blood mononuclear cells (PBMCs) were obtained from healthy controls, stage I and stage IV melanoma patients. Tregs were identified as CD4+ and CD25hi. Dendritic cells were identified using a DC cocktail of antibodies including CD11c+ myeloid dendritic cells (mDCs) and CD123+ pDCs. Serum transforming growth factor-β (TGF-β), interleukin-4 (IL-4) and interleukin-10 (IL-10) levels were determined by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using analysis of variance (ANOVA).

Results

Stage IV melanoma patients had a doubling of regulatory T cells compared to both normal subjects and stage I melanoma patients. There was a significantly higher number of DCs in all melanoma patients compared to normal subjects. Stage I melanoma patients had a significantly higher number of pDCs than normal subjects, and all melanoma patients had a higher concentration of mDCs than controls. Serum IL-4 and IL-10 were not detectable but serum TGF-β levels were significantly higher in stage I and stage IV melanoma patients compared to normal controls.

Conclusion

Advanced melanoma is associated with increased numbers of circulating dendritic cells and regulatory T cells. These data suggest that melanoma induces immunosuppressive DCs and regulatory T cells in the systemic circulation.

Keywords

Melanoma Regulatory T cells Dendritic cells Immunosuppression Human 

References

  1. 1.
    Shu S, Plautz GE, Krauss JC, Chang AE. Tumor immunology. JAMA 1997;278(22):1972–81PubMedCrossRefGoogle Scholar
  2. 2.
    Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807–39PubMedCrossRefGoogle Scholar
  3. 3.
    Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811PubMedCrossRefGoogle Scholar
  4. 4.
    Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5(4):296–306PubMedCrossRefGoogle Scholar
  5. 5.
    Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106(3):255–8PubMedCrossRefGoogle Scholar
  6. 6.
    Cox K, North M, Burke M, et al. Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J Leukoc Biol 2005;78(5):1142–52PubMedGoogle Scholar
  7. 7.
    Kuwana M. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 2002;63(12):1156–63PubMedCrossRefGoogle Scholar
  8. 8.
    Baecher-Allan CM, Hafler DA. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. Clin Immunol 2005;117(2):192; discussion 193PubMedCrossRefGoogle Scholar
  9. 9.
    Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151–64PubMedGoogle Scholar
  10. 10.
    Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193(11):1303–10PubMedCrossRefGoogle Scholar
  11. 11.
    Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9(2):606–12PubMedGoogle Scholar
  12. 12.
    Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169(5):2756–61PubMedGoogle Scholar
  13. 13.
    Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9(12):4404–8PubMedGoogle Scholar
  14. 14.
    Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98(5):1089–199PubMedCrossRefGoogle Scholar
  15. 15.
    Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942–9PubMedCrossRefGoogle Scholar
  16. 16.
    Appay V, Jandus C, Voelter V, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006;177(3):1670–8PubMedGoogle Scholar
  17. 17.
    Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173(2):1444–53PubMedGoogle Scholar
  18. 18.
    Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003;26(1):85–93PubMedCrossRefGoogle Scholar
  19. 19.
    Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24(7):1169–77PubMedCrossRefGoogle Scholar
  20. 20.
    Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005;54(12):1153–61PubMedCrossRefGoogle Scholar
  21. 21.
    Becker JC, Schwinn A, Dummer R, et al. Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression. Clin Exp Immunol 1993;91(1):121–5PubMedCrossRefGoogle Scholar
  22. 22.
    Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107(6):2409–14PubMedCrossRefGoogle Scholar
  23. 23.
    Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28(6):582–92PubMedCrossRefGoogle Scholar
  24. 24.
    Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935–45PubMedCrossRefGoogle Scholar
  25. 25.
    Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–8PubMedCrossRefGoogle Scholar
  26. 26.
    Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004;16(2):81–8PubMedCrossRefGoogle Scholar
  27. 27.
    Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/ Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002;49(3):159–66PubMedGoogle Scholar
  28. 28.
    McCarter M, Clarke J, Richter D, Wilson C. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005;138(2):321–8PubMedCrossRefGoogle Scholar
  29. 29.
    Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166(1):678–89PubMedGoogle Scholar
  30. 30.
    Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35(3–4):459–83PubMedCrossRefGoogle Scholar
  31. 31.
    Onishi H, Morisaki T, Baba E, et al. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 2002;105(3):286–95PubMedCrossRefGoogle Scholar
  32. 32.
    Wilkinson R, Kassianos AJ, Swindle P, et al. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006;66(2):180–92PubMedCrossRefGoogle Scholar
  33. 33.
    Yanagimoto H, Takai S, Satoi S, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 2005;114(1):52–60PubMedCrossRefGoogle Scholar
  34. 34.
    Bellone G, Smirne C, Mauri FA, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55(6):684–98PubMedCrossRefGoogle Scholar
  35. 35.
    Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178(5):2763–9PubMedGoogle Scholar
  36. 36.
    Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200(2):255–68PubMedCrossRefGoogle Scholar
  37. 37.
    Lebrecht A, Grimm C, Euller G, et al. Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast. Int J Biol Markers 2004;19(3):236–9PubMedGoogle Scholar
  38. 38.
    von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7(Suppl 3):925s–932sGoogle Scholar
  39. 39.
    Lin Y, Kikuchi S, Obata Y, Yagyu K. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol 2006;21(2):432–7PubMedCrossRefGoogle Scholar
  40. 40.
    Song BC, Chung YH, Kim JA, et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002;94(1):175–80PubMedCrossRefGoogle Scholar
  41. 41.
    Frumento G, Piazza T, Di Carlo E, Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006;6(3):233–7PubMedGoogle Scholar
  42. 42.
    Dunnall J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623–33CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Martin D. McCarter
    • 1
  • Joel Baumgartner
    • 1
  • Guillermo A. Escobar
    • 1
  • Donald Richter
    • 1
  • Karl Lewis
    • 2
  • William Robinson
    • 2
  • Cara Wilson
    • 3
  • Brent E. Palmer
    • 3
  • Rene Gonzalez
    • 2
  1. 1.Department of SurgeryUniversity of Colorado at Denver Health Sciences CenterDenverUSA
  2. 2.Department of Medicine, Division of Medical OncologyUniversity of Colorado at Denver Health Sciences CenterDenverUSA
  3. 3.Department of Medicine, Division of ImmunologyUniversity of Colorado at Denver Health Sciences CenterDenverUSA

Personalised recommendations